It is our general policy to use contact information, (such as e-mail address, telephone number and postal address) for internal purposes and to not sell or otherwise provide this information to third parties.
This site contains links to other web sites. We are not responsible for the privacy practices or the content of those other web sites.
Except as otherwise disclosed in this privacy statement, your personally identifiable information is not shared with any third party. For example, we do not sell, or otherwise give third parties access to, our customer list.
The information you voluntarily provide us through this site (which may include your name, company, address and contact information) will be used solely for the purposes of satisfying your requests. If you have emailed us with an inquiry, we will use your email to respond to your query. Once we have handled your request, your details may be kept for a limited period for internal administrative purposes only so we can look at what types of requests we are receiving through the website.
Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently to improve the user experience, as well as to provide certain information to the owners of the site.
They cannot be used to identify you personally.
The Egalet website sets cookies which remain on your computer for differing times. Some expire at the end of each session and some remain for longer so that when you return to our website, you will have a better user experience.
There are two types of cookie you may encounter when using the Egalet website :
First party cookies: these are our own cookies, controlled by us and used to provide information about usage of this website.
Third party cookies: these are cookies found in other companies' internet tools which we are using to enhance this website.
For more information about Google Analytics cookies:
Web browsers allow you to exercise some control of cookies through the browser settings. Most browsers enable you to block cookies or to block cookies from particular sites. Browsers can also help you to delete cookies when you close your browser. You should note however, that this may mean that any opt-outs or preferences you set on the site will be lost. To find out more about cookies, including how to see what cookies have been set and how to manage and delete them, visit www.allaboutcookies.org which includes information on how to manage your settings for the major browser providers.
We may disclose personal information if required to do so by law, court order or for the purposes of prevention of fraud or other crime or if we believe that such action is necessary to protect and defend the rights, property or personal safety of Egalet, the Egalet website or its visitors.
There is no evidence that OXAYDO® has reduced abuse liability compared to immediate-release oxycodone.
OXAYDO® (oxycodone HCl, USP) is an immediate-release oral formulation of oxycodone HCl indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
OXAYDO® is contraindicated in patients with respiratory depression, paralytic ileus, acute or severe bronchial asthma or hypercarbia, or known hypersensitivity to oxycodone or any components of the product, or in any situation where opioids are contraindicated.
Respiratory depression is a risk of OXAYDO®, especially in elderly or debilitated patients, in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, or following large initial doses of opioids given to non-tolerant patients, or when given in conjunction with other agents that depress respiration. Use with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale.
OXAYDO® is a Schedule II controlled substance with an abuse liability similar to other opioids. OXAYDO® may be abused by crushing, chewing, snorting or injecting the product and these practices pose a significant risk to the abuser that could result in overdose and death.
Patients receiving central nervous system depressants concomitantly with OXAYDO® may exhibit an additive central nervous system depression, which may result in respiratory depression, hypotension, profound sedation, or coma. Patients should not consume alcoholic beverages, or any medications containing alcohol while taking OXAYDO®.
In the presence of a head injury or other intracranial lesions, OXAYDO® may cause markedly exaggerated elevation of intracranial pressure.
OXAYDO® may cause severe hypotension in patients whose ability to maintain blood pressure has been compromised, may produce orthostatic hypotension in ambulatory patients and must be administered with caution in patients in circulatory shock.
Do not administer OXAYDO® to patients with gastrointestinal obstruction. Use OXAYDO® with caution in patients with biliary tract disease, including pancreatitis.
Use with caution and in reduced dosages in patients with severe renal or hepatic impairment, Addison’s disease, hypothyroidism, prostatic hypertrophy, or urethral stricture, and in elderly or debilitated patients. Use with caution when administering to patients with CNS depression, toxic psychosis, acute alcoholism and delirium tremens; may aggravate convulsions in patients with convulsive disorders and may induce or aggravate seizures in some clinical settings.
Keep OXAYDO® out of the reach of children.
OXAYDO® may impair mental and/or physical abilities; use with caution with potentially hazardous activities.
Concomitant use of CYP3A4 inhibitors may increase opioid effects and of CYP3A4 inducers may decrease effects or possibly cause development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.
Serious adverse reactions that may be associated with OXAYDO® include: respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension, and/or shock. The most common adverse reactions are nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia and somnolence.
Muscle relaxants: enhances the neuromuscular blocking action of skeletal muscle relaxants and produces an increased degree of respiratory depression.
Mixed agonist/antagonist analgesics: may reduce the analgesic effects and/or may precipitate withdrawal symptoms.
Monoamine Oxidase Inhibitors (MAOIs): use not recommended with or within 14 days of stopping MAOIs.
Anticholinergics: increased risk for urinary retention and severe constipation.